LAUSR

Background Bisphosphonates are recommended in patients with osteoporosis patients. clinical concerns had been considered in kidney safety. Objectives This study investigated the safety of bisphosphonate effects on renal function in patients with magnetic resonance imaging (MRI)-proven acute osteoporotic vertebral fractures after vertebroplasty. Methods This retrospective study was conducted in osteoporotic patients with acute vertebral fractures treated with vertebroplasty between January 2001 and December 2015. Their gender, age, body mass index (BMI, kg/m2), co-morbidities were recorded, as well as their use of zolendronic acid. Those with increase in creatinine was defined as progress of renal function. Logistical regression was used to adjust the variables. Results There were 989 patients (783 females; mean age, 74.08±9.26 years). 71patients accepted zolendronic acid, the others accept other anti-osteoporotic agents. 35 (49.3%) of zolendronic acid had increased creatinine, while 379 (41.3%) of non-zolendronic acid had creatinine changes (p=0.117). After adjust variables, zolendronic acid did not increase creatinine (p=0.291; OR: 0.750; 95% CI: 0.440–1.279).(Table 1)Table 1. Risk of increase in renal function in zolendronic acid after adjust variables Regression coefficient S.E. Wald P value OR 95% C.I.for OR Lower Upper Zoledronic acid -0.288 0.273 1.116 0.291 0.750 0.440 1.279 Smoking 0.250 0.343 0.533 0.465 1.284 0.656 2.513 Alcohol 0.025 0.065 0.147 0.702 1.025 0.903 1.164 BMI 0.007 0.017 0.160 0.689 1.007 0.974 1.040 DM -0.165 0.164 1.022 0.312 0.848 0.615 1.168 HTN -0.418 0.149 7.856 0.005 0.658 0.491 0.882 Conclusions Zolendronic acid use did not lead to increase in creatinine as compared with the control group. However it need more cases to confirm this findings. References Miller PD Bone. 2011 Jul;49(1):77–81. Acknowledgements We thanks Chang Gang Memorial Hospital for data support. Disclosure of Interest None declared